{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-142904","form_type":"8-K","ticker":"NBIX","cik":"0000914475","company_name":"NEUROCRINE BIOSCIENCES INC","filed_at":"2026-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.928616+00:00","generated_at":"2026-05-15T07:29:35.058526+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Neurocrine to acquire Soleno Therapeutics for $53.00 per share in cash","bullets":["Tender offer for all Soleno shares at $53.00 cash each; no financing condition.","Offer requires >50% shares tendered, HSR clearance, no material adverse effect.","Termination fees: Soleno pays $95.25M for superior proposal; Neurocrine pays $141.5M for antitrust failure.","Soleno board recommends tender; CEO and former CFO (1.01% combined) signed support agreements.","Deal structured as tender offer followed by merger under Section 251(h) of DGCL."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-142904","json":"https://secwatch.observer/filing/0001193125-26-142904.json","markdown":"https://secwatch.observer/filing/0001193125-26-142904.md","text":"https://secwatch.observer/filing/0001193125-26-142904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/0001193125-26-142904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/d110123d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:29:35.058526+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d384db782216276093cc91c172feb4a43da357d3","claim":"NEUROCRINE BIOSCIENCES INC entered into Merger Agreement with Soleno Therapeutics, Inc. (effective 2026-04-05).","evidence_excerpt":"On April 5, 2026, Neurocrine Biosciences, Inc., a Delaware corporation (“ Neurocrine ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Neurocrine, Sigma Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Neurocrine (“ Purchaser ”), and Soleno Therapeutics, Inc., a Delaware corporation (“ Soleno ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914475/000119312526142904/0001193125-26-142904-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Soleno Therapeutics, Inc."},{"label":"Effective","value":"2026-04-05"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}